Dr. Bryce on Ongoing Research in Prostate Cancer

Alan H. Bryce, MD, assistant professor of medicine and medical director of the Genomic Oncology Clinic, Mayo Clinic, discusses ongoing research in prostate cancer.

The ongoing phase III AFT19 trial is evaluating apalutamide (Erleada) in patients with biochemically relapsed disease. In the 3-arm study, patients will be randomized to receive either androgen deprivation therapy (ADT) alone, ADT plus apalutamide, or ADT, apalutamide, and abiraterone acetate (Zytiga).

Similar to the phase III CHAARTED and STAMPEDE studies, AFT19 is trying to take effective agents and bring them into earlier-line settings, which could potentially translate to significant improvements in overall survival, explains Bryce.

In addition, more studies taking approved agents in metastatic castration-resistant disease and moving them into the hormone-sensitive and nonmetastatic setting are expected, concludes Bryce.